Amalgamated Financial’s Cardlytics CDLX Stock Holding History

Amalgamated Financial’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$290K	Buy	+528	New	+$319K	﹤0.01%	1748

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

ACM

Alua Capital Management New York $1.13B AUM 8.41% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

JCM

JS Capital Management New York $109M AUM 34.13% 1-Year Est. Return

Amalgamated Financial's CDLX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Cardlytics (CDLX) in Q1 2022: 528 shares worth $290K. The stake represents ﹤0.01% of the portfolio and ranks #1748 among its holdings.

153 funds tracked by Wall St. Rank hold CDLX as of Q1 2022.

Amalgamated Financial held 528 shares of Cardlytics worth $290K as of Q1 2022.
Cardlytics was a new Amalgamated Financial position in Q1 2022.
Cardlytics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1748 holding.
153 funds tracked by Wall St. Rank held Cardlytics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.